|
COVID-19 outcomes in patients with cancer and HIV: An analysis of the COVID-19 and Cancer Consortium (CCC19). |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Pfizer; Sanofi Pasteur |
Consulting or Advisory Role - Janssen; MSD; Pfizer |
Travel, Accommodations, Expenses - Pfizer |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Research Funding - Astellas Pharma (Inst); Merck (Inst); Viracor Eurofins (Inst) |
|
|
Honoraria - Incrowd; M3; Massive Bio; Sermo |
Other Relationship - Onclive |
|
Francisco J. Hernandez-Ilizaliturri |
Consulting or Advisory Role - Amgen; Celgene; GlaxoSmithKline; Kite/Gilead; Novartis; Pharmacyclics; Seagen; Takeda |
|
|
|
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Research Funding - Amgen (Inst); Bicycle Therapeutics (Inst); Boehringer Ingelheim (Inst); Ikena Oncology (Inst); KAHR Medical (Inst); Merck (Inst); RasCal (Inst); Syros Pharmaceuticals (Inst); Tarveda Therapeutics (Inst) |
|
|
No Relationships to Disclose |
|
|
Employment - MilliporeSigma (I) |
Other Relationship - National Geographic |
|
|
Stock and Other Ownership Interests - HemOnc.org |
Consulting or Advisory Role - Flatiron Health; Melax Tech; Roche; Westat |
|
|
Employment - EpicentRx (I) |
Leadership - EpicentRx (I) |
Stock and Other Ownership Interests - EpicentRx (I) |
Research Funding - Abbvie (Inst); ADC Therapeutics (Inst); Aptose Biosciences (Inst); Millenium Pharamceuticals (Inst); Xencor (Inst) |
Patents, Royalties, Other Intellectual Property - Husband hold multiple patents related to lymphedema management, oncolytic viral therapy. (I) |